Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma - commentary.
Recent publications suggested that pasireotide could be a good therapeutic option in some dopamine resistant or aggressive prolactinomas. We discussed the 2 published cases and describe another case of poorly-differentiated plurihormonal PIT-1 positive adenoma with moderate SSTR2 expression and intense STTR5 expression succeffuly treated with PAS-LAR 40mg/month.